ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $14,297.50 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 250 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $57.19, for a total transaction of $14,297.50. Following the completion of the sale, the vice president now directly owns 56,488 shares of the company’s stock, valued at approximately $3,230,548.72. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Friday, September 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $56.82, for a total transaction of $14,205.00.
• On Tuesday, August 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $59.62, for a total transaction of $14,905.00.

ANI Pharmaceuticals Price Performance

Shares of ANIP traded up $0.10 during trading hours on Tuesday, reaching $58.60. 164,587 shares of the stock traded hands, compared to its average volume of 213,293. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals, Inc. has a 52-week low of $48.20 and a 52-week high of $70.81. The company’s 50-day moving average price is $59.41 and its two-hundred day moving average price is $62.55. The company has a market cap of $1.23 billion, a P/E ratio of 36.63 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The company had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $129.09 million. During the same quarter in the previous year, the company earned $1.06 EPS. ANI Pharmaceuticals’s revenue for the quarter was up 18.5% on a year-over-year basis. On average, analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

ANIP has been the subject of a number of recent research reports. Piper Sandler initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday. They set an “overweight” rating and a $68.00 price objective for the company. Raymond James boosted their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th. Truist Financial reissued a “hold” rating and set a $60.00 price objective (down previously from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Finally, StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $77.00.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds have recently bought and sold shares of ANIP. Innealta Capital LLC purchased a new stake in ANI Pharmaceuticals in the 2nd quarter worth $65,000. Ridgewood Investments LLC purchased a new stake in ANI Pharmaceuticals in the 2nd quarter worth $85,000. SG Americas Securities LLC purchased a new stake in ANI Pharmaceuticals in the 1st quarter worth $106,000. XTX Topco Ltd purchased a new stake in ANI Pharmaceuticals in the 2nd quarter worth $207,000. Finally, O Shaughnessy Asset Management LLC purchased a new stake in ANI Pharmaceuticals in the 1st quarter worth $218,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.